JPH101438A - External preparation for skin - Google Patents

External preparation for skin

Info

Publication number
JPH101438A
JPH101438A JP8173082A JP17308296A JPH101438A JP H101438 A JPH101438 A JP H101438A JP 8173082 A JP8173082 A JP 8173082A JP 17308296 A JP17308296 A JP 17308296A JP H101438 A JPH101438 A JP H101438A
Authority
JP
Japan
Prior art keywords
skin
extract
preparation
benzoquinones
actions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP8173082A
Other languages
Japanese (ja)
Inventor
Masumi Takei
増美 竹井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noevir Co Ltd
Original Assignee
Noevir Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noevir Co Ltd filed Critical Noevir Co Ltd
Priority to JP8173082A priority Critical patent/JPH101438A/en
Publication of JPH101438A publication Critical patent/JPH101438A/en
Pending legal-status Critical Current

Links

Landscapes

  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PROBLEM TO BE SOLVED: To obtain a preparation for external use for skin, comprising an extract of a specific myrsinaceous plant or 1,4-benzoquinones contained in the extract as an active ingredient and having preventing effects on aging, antiinflammatory and beautifying and whitening effects together. SOLUTION: This preparation for external use comprises an extract of Ardisia japonica Blume, Ardisia quinquegona Blume and Ardisia sieboldi Miq. or 1,4-benzoquinones contained in the extract as an active ingredient. The blending concentration of the extract in the preparation for external use is about 0.1-1μM expressed in terms of the 1,4-benzoquinones and about 0.001-10wt.% in a state of a crude extract of the plant. The active ingredient has good scavenging actions on active oxygen species and further antiinflammatory actions based on inhibiting actions on 5-lipoxygenases and beautifying and whitening actions based on inhibiting actions, etc., on tyrosinases. The preparation is effective in reducing and preventing aging diseases of the skin mainly caused by oxidative stress, dermatitis, pigmentation such as dermal stains, ephelides or nevus Ota, blackening, etc., due to sunburn.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、老化防止効果,抗
炎症効果及び美白効果を合わせ持つ皮膚外用剤に関す
る。さらに詳しくは、特定のヤブコウジ科植物の抽出物
或いはその抽出物中に含まれる1,4-ベンゾキノン類を含
有して成る皮膚外用剤に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an external preparation for skin having an anti-aging effect, an anti-inflammatory effect and a whitening effect. More specifically, the present invention relates to an external preparation for skin comprising an extract of a specific Aspergillus or a 1,4-benzoquinone contained in the extract.

【0002】[0002]

【従来の技術】皮膚は、熱,紫外線,種々の化学物質
等、環境中に存在する種々のストレスにさらされてい
る。その結果、皮膚においては紅斑,浮腫といった炎症
反応や、アレルギー反応、メラニン生成による黒化とい
った反応が生じ、さらに長期間にわたりかかるストレス
にさらされた結果、皮膚のしわやしみの発生,弾力の低
下といった老化症状が進行することが明らかにされてき
ている。
2. Description of the Related Art Skin is exposed to various stresses existing in the environment, such as heat, ultraviolet rays, and various chemical substances. As a result, inflammatory reactions such as erythema and edema, allergic reactions, and blackening due to melanin production occur on the skin. As a result of being subjected to the stress for a long period of time, wrinkles and wrinkles of the skin occur, and elasticity decreases. It has been revealed that such aging symptoms progress.

【0003】従って、上記の炎症等を防止し、皮膚の黒
化や老化を防止するような有効成分の探求が行われ、そ
れらを含有する皮膚外用剤の提供が試みられてきた。た
とえば、抗炎症剤としてはβ-グリチルレチン酸,グリ
チルリチン酸,それらの塩及び誘導体、アラントイン及
びその誘導体、アズレン,ε-アミノカプロン酸,ハイ
ドロコルチゾン等、アレルギー症状の緩和には、塩酸ジ
フェンヒドラミン,マレイン酸クロルフェニラミン等の
抗ヒスタミン剤が用いられ、美白剤としては、アスコル
ビン酸及びその誘導体,コウジ酸及びその誘導体,アル
ブチン等のハイドロキノン誘導体等が用いられている。
また近年、酸化ストレスによる皮膚の老化がクローズア
ップされ、ビタミンEやスーパーオキシドディスムター
ゼ等、活性酸素種の消去剤の配合も行われている。
[0003] Therefore, active ingredients that prevent the above-mentioned inflammation and the like and prevent darkening and aging of the skin have been sought, and attempts have been made to provide external skin preparations containing them. For example, anti-inflammatory agents include β-glycyrrhetinic acid, glycyrrhizic acid, salts and derivatives thereof, allantoin and its derivatives, azulene, ε-aminocaproic acid, hydrocortisone, and the like. Antihistamines such as phenylamine are used, and as whitening agents, ascorbic acid and its derivatives, kojic acid and its derivatives, hydroquinone derivatives such as arbutin and the like are used.
In recent years, aging of skin due to oxidative stress has been highlighted, and elimination agents for active oxygen species such as vitamin E and superoxide dismutase have been added.

【0004】しかしながら、従来用いられていた上記の
成分には、光や熱等に対して不安定なものが多く、また
作用,効果が不十分で、外用剤基剤に配合して十分な効
果を得るには、かなりの多量を配合する必要があった。
さらに、老化防止,抗炎症及び美白と、すべての効果を
合わせて発揮し得る成分は少なく、これらの効果をまん
べんなく発揮させるには、多種類の成分を併用する必要
があり、併用する成分によっては、それぞれの安定性及
び作用の低減を来すこともあった。
[0004] However, many of the above-mentioned components which have been conventionally used are unstable to light and heat, etc., and their actions and effects are insufficient. In order to obtain, it was necessary to blend a considerably large amount.
Furthermore, there are few components that can exhibit all effects together with anti-aging, anti-inflammatory, and whitening. To achieve these effects evenly, it is necessary to use various types of components in combination, and depending on the components used in combination, In some cases, the stability and action of each may be reduced.

【0005】[0005]

【発明が解決しようとする課題】本発明は上記のような
問題点の解消を図り、少量,少種類の有効成分を含有す
るのみで、老化防止,抗炎症及び美白の各効果を合わせ
持ち、且つ安定性及び安全性に優れる皮膚外用剤を提供
することを目的とする。
SUMMARY OF THE INVENTION The present invention has been made to solve the above-mentioned problems, and has only the effects of anti-aging, anti-inflammatory and whitening by containing only a small amount and a small number of active ingredients. Another object of the present invention is to provide an external preparation for skin that is excellent in stability and safety.

【0006】[0006]

【課題を解決するための手段】上記課題を解決するため
種々検討を行ったところ、ヤブコウジ科に属する特定の
植物の抽出物が老化防止効果,抗炎症効果及び美白効果
を合わせ持つことを見い出し、その抽出物を皮膚外用剤
に含有させることにより良好な結果を得、本発明を完成
するに至った。
Various studies have been carried out to solve the above-mentioned problems. As a result, it has been found that an extract of a specific plant belonging to the family Astragalus has a combination of an anti-aging effect, an anti-inflammatory effect and a whitening effect. By including the extract in a skin external preparation, good results were obtained, and the present invention was completed.

【0007】ヤブコウジ科に属する植物の中では、マン
リョウ(Ardisia crenata Sims)の根等の抽出物が美白
作用及び抗炎症作用を合わせ持つことが知られている
(特開平4−346912)が、今回の検討により、ヤ
ブコウジ(Ardisia japonica Blume),シシアクチ(A.
quinquegona Blume),及びモクタチバナ(A. siebold
i Miq.)の抽出物が、優れた皮膚の老化防止,抗炎症及
び美白の各効果を合わせ持つことが明らかになった。
[0007] Among plants belonging to the family Astridaceae, it is known that extracts such as roots of Manryou ( Ardisia crenata Sims) have both a whitening effect and an anti-inflammatory effect (JP-A-4-346912). the study of, Ardisia japonica (Ardisia japonica Blume), Shishiakuchi (a.
quinquegona Blume) and mokutachibana ( A. siebold)
i Miq.) extract has excellent skin anti-aging, anti-inflammatory and whitening effects.

【0008】すなわち、本発明においては、ヤブコウジ
Ardisia japonica Blume),シシアクチ(A. quinque
gona Blume),及びモクタチバナ(A. sieboldi Miq.)
の各抽出物より、1種又は2種以上を選択して外用剤基
剤に含有させる。前記植物の抽出に用いる部位として
は、葉,樹皮,花,果実,根,地下茎等、いずれの部位
を用いても良いが、葉が特に好ましい。これらの各部位
は、生のまま細切して抽出に供しても良いが、乾燥して
粉砕し、粉末状として抽出を行うことが、抽出効率の上
で最も好ましい。
Namely, in the present invention, Ardisia japonica (Ardisia japonica Blume), Shishiakuchi (A. Quinque
gona Blume) and mokutachibana ( A. sieboldi Miq.)
One or two or more types are selected from each of the above extracts to be contained in the external preparation base. As the site used for extracting the plant, any site such as leaf, bark, flower, fruit, root, rhizome, etc. may be used, but leaves are particularly preferable. Each of these parts may be cut into raw pieces and subjected to extraction, but it is most preferable to dry, pulverize and extract as a powder in terms of extraction efficiency.

【0009】抽出溶媒としては、水の他、メタノール,
エタノール,プロパノール,イソプロパノール,1,3-ブ
チレングリコール,プロピレングリコール等のアルコー
ル類、酢酸エチル,アセトン等の極性の高い有機溶媒よ
り1種又は2種以上を用いることができるが、アルコー
ル類により抽出するのが最も好ましい。
As an extraction solvent, in addition to water, methanol,
One or more alcohols such as ethanol, propanol, isopropanol, 1,3-butylene glycol, and propylene glycol, and highly polar organic solvents such as ethyl acetate and acetone can be used. Is most preferred.

【0010】また、抽出物はそのままでも外用剤基剤に
添加できるが、水,アルコール等の溶媒で希釈したり、
脱色,脱臭等の処理を行った後に添加することもでき
る。さらに、Fukuyamaらの方法(Chem. Pharm.
Bull. 43 (8) 1391-1394 (1995))等により精製を行
い、より有効成分の濃度の高い画分として含有させても
良い。特に、前記精製操作により分取される1,4-ベンゾ
キノン類を含有させると、非常に高い活性を有するた
め、低濃度で十分な効果を発揮させることができる。
The extract can be added to the external preparation base as it is, but it can be diluted with a solvent such as water or alcohol,
It can also be added after treatment such as decolorization and deodorization. Furthermore, the method of Fukuyama et al. (Chem. Pharm.
Bull. 43 (8) 1391-1394 (1995)) or the like, and may be contained as a fraction having a higher concentration of the active ingredient. In particular, when 1,4-benzoquinones fractionated by the above-mentioned purification operation are contained, they have extremely high activity, so that a sufficient effect can be exerted at a low concentration.

【0011】なお本発明においては、ヤブコウジ等の抽
出物又はそれらより単離される1,4-ベンゾキノン類に加
えて、他の活性酸素種消去剤や抗炎症剤、美白剤の他、
油類,保湿剤,紫外線吸収剤,香料,防腐剤等、一般的
な外用剤及び化粧料用原料をも含有させることができ
る。
In the present invention, in addition to extracts such as Aspergillus oryzae or 1,4-benzoquinones isolated therefrom, other active oxygen species scavengers, anti-inflammatory agents, whitening agents, etc.
General external preparations such as oils, humectants, ultraviolet absorbers, fragrances, preservatives, and raw materials for cosmetics can also be contained.

【0012】[0012]

【作用】本発明において有効成分として含有させるヤブ
コウジ等の抽出物及びそれらより単離される1,4-ベンゾ
キノン類は、良好な活性酸素種の消去作用を有し、合わ
せて5-リポキシゲナーゼ阻害活性等に基づく抗炎症作
用、及びチロシナーゼ阻害作用等による美白作用を有す
る。従って、本発明に係る皮膚外用剤は、主に酸化的ス
トレスに起因する皮膚の老化症状の改善及び防止、皮膚
における炎症の治療及び防止、及びしみ,そばかすをは
じめ太田母斑等の色素沈着症や日焼けによる黒化の改善
及び防止において、優れた作用,効果を示す。
The extracts of Aspergillus oryzae and the like, and the 1,4-benzoquinones isolated therefrom, have good elimination of reactive oxygen species and, in addition, 5-lipoxygenase inhibitory activity. It has an anti-inflammatory action based on tyrosinase and a whitening action by tyrosinase inhibitory action and the like. Therefore, the external preparation for skin according to the present invention is useful for improving and preventing aging symptoms of the skin mainly due to oxidative stress, treating and preventing inflammation in the skin, and pigmentation diseases such as spots, freckles, and nevus of Ota. In the improvement and prevention of blackening due to sunburn and sunburn, it has excellent action and effects.

【0013】外用剤への配合濃度としては、1,4-ベンゾ
キノン類にして0.1〜1μM程度で有効な効果が認め
られる。植物の粗抽出物の状態でも、0.001〜10
重量%程度の配合で十分な効果が認められる。
An effective effect is recognized when the compounding concentration in the external preparation is about 0.1 to 1 μM in terms of 1,4-benzoquinone. Even in the state of a crude plant extract, 0.001 to 10
Sufficient effects are observed with a blending of about weight%.

【0014】[0014]

【発明の実施の形態】本発明は、ローション剤,乳剤,
ゲル剤,クリーム,軟膏等の剤型の皮膚外用剤として提
供することができる。また、化粧水,乳液,クリーム等
の皮膚用化粧料としても提供され得る。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a lotion, an emulsion,
It can be provided as a skin external preparation in the form of a gel, cream, ointment or the like. In addition, it can be provided as a skin cosmetic such as lotion, milky lotion, cream and the like.

【0015】[0015]

【実施例】さらに本発明について、実施例により詳細に
説明する。
EXAMPLES The present invention will be described in more detail with reference to Examples.

【0016】 [実施例1] 皮膚用ローション剤 (1)エタノール 10.0(重量%) (2)ヒドロキシエチルセルロース 1.0 (3)ヤブコウジ葉エタノール抽出物 5.0 (4)精製水 84.0 製法:(1)〜(4)を混合し均一とする。[Example 1] Skin lotion (1) Ethanol 10.0 (wt%) (2) Hydroxyethylcellulose 1.0 (3) Aspergillus niger leaf ethanol extract 5.0 (4) Purified water 84.0 Production method: (1) to (4) are mixed and made uniform.

【0017】 [実施例2] 皮膚用乳剤 (1)ステアリン酸 0.2(重量%) (2)セタノール 1.5 (3)ワセリン 3.0 (4)流動パラフィン 7.0 (5)ポリオキシエチレン(10E.O.)モノオレイン酸 1.5 エステル (6)酢酸トコフェロール 5.0 (7)グリセリン 5.0 (8)パラオキシ安息香酸メチル 0.1 (9)トリエタノールアミン 1.0 (10)精製水 71.7 (11)シシアクチ葉メタノール抽出物 2.0 (12)モクタチバナ葉酢酸エチル抽出物 2.0 製法:(1)〜(6)の油相成分を混合,加熱して均一に溶解
し、70℃に保つ。一方、(7)〜(10)の水相成分を混
合,加熱して均一とし、70℃とする。この水相成分に
前記油相成分を攪拌しながら徐々に添加して乳化し、冷
却した後40℃にて(11),(12)を添加する。
Example 2 Skin Emulsion (1) Stearic acid 0.2 (% by weight) (2) Cetanol 1.5 (3) Vaseline 3.0 (4) Liquid paraffin 7.0 (5) Polyoxy Ethylene (10E.O.) monooleic acid 1.5 ester (6) Tocopherol acetate 5.0 (7) Glycerin 5.0 (8) Methyl parahydroxybenzoate 0.1 (9) Triethanolamine 1.0 (10 ) Purified water 71.7 (11) Sciatica leaf methanol extract 2.0 (12) Motachibana leaf ethyl acetate extract 2.0 Production method: Mix and heat the oil phase components of (1) to (6) Dissolve and keep at 70 ° C. On the other hand, the aqueous phase components (7) to (10) are mixed and heated to be uniform, and the temperature is set to 70 ° C. The oil phase component is gradually added to the aqueous phase component while stirring to emulsify, and after cooling, (11) and (12) are added at 40 ° C.

【0018】 [実施例3] 皮膚用ゲル剤 (1)ジプロピレングリコール 10.0(重量%) (2)カルボキシビニルポリマー 0.5 (3)水酸化カリウム 0.1 (4)パラオキシ安息香酸メチル 0.1 (5)精製水 84.3 (6)アスコルビン酸リン酸エステルマグネシウム塩 4.0 (7)1,4-ベンゾキノン類含有画分エタノール溶液 1.0 (1,4-ベンゾキノン類含量;100μM) 製法:(5)に(2)を均一に溶解させた後、(1)に(4)を溶解
させて添加し、次いで(3)を加えて増粘させ、(6),(7)
を添加する。
Example 3 Skin Gel (1) Dipropylene glycol 10.0 (% by weight) (2) Carboxyvinyl polymer 0.5 (3) Potassium hydroxide 0.1 (4) Methyl paraoxybenzoate 0.1 (5) Purified water 84.3 (6) Ascorbic acid phosphate magnesium salt 4.0 (7) 1,4-benzoquinone-containing fraction ethanol solution 1.0 (1,4-benzoquinone content; (100 μM) Production method: After dissolving (2) uniformly in (5), dissolve (4) in (1) and then add (3) to increase the viscosity, (6), (7) )
Is added.

【0019】 [実施例4] 皮膚用クリーム (1)ミツロウ 6.0(重量%) (2)セタノール 5.0 (3)還元ラノリン 8.0 (4)スクワラン 27.5 (5)グリセリル脂肪酸エステル 4.0 (6)親油型グリセリルモノステアリン酸エステル 2.0 (7)ポリオキシエチレン(20E.O.)ソルビタン 5.0 モノラウリン酸エステル (8)プロピレングリコール 5.0 (9)パラオキシ安息香酸メチル 0.1 (10)精製水 30.4 (11)レチノールパルミチン酸エステル 1.0 (12)ヤブコウジ葉50重量%プロピレン 3.0 グリコール抽出物 (13)モクタチバナ葉50重量%1,3-ブチレン 3.0 グリコール抽出物 製法:(1)〜(7)の油相成分を混合,溶解して75℃に加
熱する。一方、(8)〜(10)の水相成分を混合,溶解して
75℃に加熱する。次いで、上記水相成分に油相成分を
添加して予備乳化した後、ホモミキサーにて均一に乳化
し、冷却後40℃にて(11)〜(13)を添加する。
Example 4 Skin Cream (1) Beeswax 6.0 (% by weight) (2) Cetanol 5.0 (3) Reduced Lanolin 8.0 (4) Squalane 27.5 (5) Glyceryl fatty acid ester 4.0 (6) Lipophilic glyceryl monostearate 2.0 (7) Polyoxyethylene (20E.O.) sorbitan 5.0 Monolaurate (8) Propylene glycol 5.0 (9) Paraoxybenzoic acid Methyl 0.1 (10) Purified water 30.4 (11) Retinol palmitate 1.0 (12) 50% by weight of Aspergillus niger leaf Propylene 3.0 Glycol extract (13) 50% by weight of Motachibana leaf 1,3-butylene 3.0 Glycol extract Production method: Mix and dissolve the oil phase components (1) to (7) and heat to 75 ° C. On the other hand, the aqueous phase components (8) to (10) are mixed and dissolved, and heated to 75 ° C. Next, the oil phase component is added to the water phase component and pre-emulsified, and then uniformly emulsified by a homomixer. After cooling, (11) to (13) are added at 40 ° C.

【0020】 [実施例5] 水中油型乳剤性軟膏 (1)白色ワセリン 25.0(重量%) (2)ステアリルアルコール 25.0 (3)グリセリン 12.0 (4)ラウリル硫酸ナトリウム 1.0 (5)パラオキシ安息香酸メチル 0.1 (6)精製水 33.9 (7)レチノイン酸 0.5 (8)ヤブコウジ葉50重量%プロパノール抽出物 1.5 (9)シシアクチ葉60重量%エタノール抽出物 0.5 (10)モクタチバナ葉60重量%エタノール抽出物 0.5 製法:(1)〜(4)の油相成分を混合,溶解して均一とし、
75℃に加熱する。一方、(5)及び(6)の水相成分を混
合,溶解して75℃に加熱し、これに前記油相成分を添
加して乳化し、冷却後40℃にて(7)〜(10)を添加,混
合する。
Example 5 Oil-in-water emulsion ointment (1) White petrolatum 25.0 (% by weight) (2) Stearyl alcohol 25.0 (3) Glycerin 12.0 (4) Sodium lauryl sulfate 1.0 (5) Methyl paraoxybenzoate 0.1 (6) Purified water 33.9 (7) Retinoic acid 0.5 (8) Extract of 50% by weight of Aspergillus niger leaf propanol 1.5 (9) Extraction of ethanol by 60% by weight of Sicicuti leaf Material 0.5 (10) Motachibana leaf 60% by weight ethanol extract 0.5 Production method: Mix and dissolve the oil phase components of (1) to (4) to make uniform,
Heat to 75 ° C. On the other hand, the aqueous phase components (5) and (6) were mixed and dissolved, heated to 75 ° C., added with the oil phase component and emulsified, cooled, and then cooled to 40 ° C. at (7) to (10). ) Is added and mixed.

【0021】 [実施例6] 化粧水 (1)エタノール 10.0(重量%) (2)1,3-ブチレングリコール 5.0 (3)パラオキシ安息香酸メチル 0.1 (4)モクタチバナ全木エタノール抽出物 0.5 (5)香料 0.1 (6)精製水 84.3 製法:(1)〜(5)を順次(6)に添加して均一に混合,溶解
する。
[Example 6] Lotion (1) Ethanol 10.0 (wt%) (2) 1,3-butylene glycol 5.0 (3) Methyl parahydroxybenzoate 0.1 (4) Mokutachibana whole tree ethanol Extract 0.5 (5) Fragrance 0.1 (6) Purified water 84.3 Production method: (1) to (5) are sequentially added to (6) and uniformly mixed and dissolved.

【0022】 [実施例7] エモリエントクリーム(油中水型) (1)流動パラフィン 30.0(重量%) (2)マイクロクリスタリンワックス 2.0 (3)ワセリン 5.0 (4)ジグリセリルジオレイン酸エステル 5.0 (5)L-グルタミン酸ナトリウム 1.6 (6)L-セリン 0.4 (7)プロピレングリコール 3.0 (8)パラオキシ安息香酸メチル 0.1 (9)精製水 52.4 (10)ヤブコウジ樹皮,葉50重量%プロピレン 0.2 グリコール抽出物 (11)シシアクチ葉,花,果実1,3-ブチレン 0.2 グリコール抽出物 (12)香料 0.1 製法:(5),(6)を(9)の一部に溶解して50℃とし、5
0℃に加熱した(4)に攪拌しながら徐々に添加する。こ
れをあらかじめ混合し70℃に加熱溶解した(1)〜(3)に
均一に分散し、これに(7),(8)を(9)の残部に溶解して
70℃に加熱したものを攪拌しながら添加し、ホモミキ
サーにて乳化する。冷却後、40℃にて(10)〜(12)を添
加,混合する。
Example 7 Emollient cream (water-in-oil type) (1) Liquid paraffin 30.0 (% by weight) (2) Microcrystalline wax 2.0 (3) Vaseline 5.0 (4) Diglyceryl geo Leic acid ester 5.0 (5) Sodium L-glutamate 1.6 (6) L-serine 0.4 (7) Propylene glycol 3.0 (8) Methyl parahydroxybenzoate 0.1 (9) Purified water 52. 4 (10) Aspergillus bark, leaf 50% by weight propylene 0.2 glycol extract (11) Siciakuchi leaf, flower, fruit 1,3-butylene 0.2 glycol extract (12) Fragrance 0.1 Production method: (5) , (6) dissolved in a part of (9) to 50 ° C.
Add slowly to (4) heated to 0 ° C. with stirring. This was previously mixed and uniformly dispersed in (1) to (3), which were heated and dissolved at 70 ° C., and (7) and (8) were dissolved in the remainder of (9) and heated to 70 ° C. Add while stirring and emulsify with a homomixer. After cooling, (10) to (12) are added and mixed at 40 ° C.

【0023】上記実施例のうち、実施例1及び実施例3
について、老化防止効果,抗炎症効果及び美白効果を評
価した。その際、実施例1において、(3)のヤブコウジ
葉エタノール抽出物を同量の酢酸トコフェロールに代替
したものを比較例1、実施例3において、(7)の1,4-ベ
ンゾキノン類含有画分エタノール溶液をエタノールに代
替したものを比較例2とし、同様に評価を行った。
Of the above embodiments, the first and third embodiments
Were evaluated for their anti-aging, anti-inflammatory and whitening effects. At that time, in Example 1, the ethanol extract of Aspergillus niger leaves (3) was replaced with the same amount of tocopherol acetate in Comparative Example 1 and in Example 3, the fraction containing (1,7) -benzoquinones in (7) was used. The same evaluation was performed with Comparative Example 2 in which the ethanol solution was replaced with ethanol.

【0024】まず、皮膚の老化防止効果として、ヘアレ
スマウスにおけるしわの発生に対する効果を評価した。
評価は、ヘアレスマウス5匹を1群とし、各群について
実施例及び比較例をそれぞれ1日1回背部に塗布し、1
J/cm2/週の長波長紫外線(UVA)を50週間照射
し、ヘアレスマウス背部皮膚におけるしわの発生状況を
観察し、表1に示す判定基準に従って点数化して行っ
た。この際、精製水のみを塗布した群を対照とした。結
果は、各群の平均値を算出し、UVA照射日数との関係
により表2に示した。
First, as an effect of preventing skin aging, the effect on the occurrence of wrinkles in hairless mice was evaluated.
In the evaluation, five hairless mice were used as one group, and the examples and the comparative examples were applied to the back once a day for each group.
The hairless mice were irradiated with long-wavelength ultraviolet light (UVA) for 50 weeks at J / cm 2 / week, the occurrence of wrinkles on the back skin of the hairless mouse was observed, and scored according to the criteria shown in Table 1. At this time, a group to which only purified water was applied was used as a control. The results are shown in Table 2 by calculating the average value of each group and showing the relationship with the number of UVA irradiation days.

【表1】 [Table 1]

【0025】次に抗炎症効果は、ヘアレスマウス5匹を
1群とし、背部にカラギーナン水溶液を皮下注射して炎
症を惹起した後、実施例及び比較例をそれぞれ1日1回
1週間連続して背部皮膚に塗布し、炎症の改善状況を観
察して評価した。この際も、精製水のみを塗布した群を
対照とした。炎症の改善状況は、「改善」,「やや改
善」,「改善を認めず」の3段階にて評価し、各評価を
得たヘアレスマウスの数にて表3に示した。
Next, the anti-inflammatory effect was determined by injecting a carrageenan aqueous solution subcutaneously into the back of a group of 5 hairless mice to induce inflammation. It was applied to the back skin, and the state of improvement of inflammation was observed and evaluated. At this time, the group to which only purified water was applied was used as a control. The state of improvement of inflammation was evaluated in three stages of “improvement”, “slight improvement”, and “no improvement”, and the number of hairless mice that obtained each evaluation was shown in Table 3.

【0026】続いて肌荒れに対する改善効果を評価し
た。顕著な肌荒れ症状を有する女性パネラー20名を1
群とし、各群に実施例及び比較例のそれぞれを1日2
回、ブラインドにて1カ月間連続使用させ、1カ月後の
皮膚の症状を観察して、使用開始前と比較した。皮膚の
肌荒れ症状は表4に示す判定基準に従って点数化し、2
0名の平均値を算出し、表5に示した。
Subsequently, the effect of improving skin roughness was evaluated. 1 female panelist with significant skin irritation
In each group, each of Examples and Comparative Examples was given 2 times a day.
The skin was used continuously for one month with a blind for one month, and the skin symptoms after one month were observed and compared with those before the start of use. The skin roughening symptoms were scored according to the criteria shown in Table 4 to give a score of 2
The average value of 0 subjects was calculated and is shown in Table 5.

【表4】 [Table 4]

【0027】最後に色素沈着症状の改善効果を評価し
た。顕著なシミ,ソバカス等の色素沈着症状を有する女
性パネラー20名を1群とし、各群に実施例及び比較例
をそれぞれブラインドにて1日2回ずつ1カ月間使用さ
せ、1カ月後の皮膚の色素沈着の状態を観察して使用前
と比較した。色素沈着の状況は表6に示す判定基準に従
って評価し、20名の平均値を算出し、表5にまとめて
示した。
Finally, the effect of improving pigmentation symptoms was evaluated. A group of 20 female panelists with remarkable pigmentation symptoms such as spots and freckles was used as a group, and the examples and comparative examples were each used twice a day blindly for one month for each group, and the skin after one month was used. The state of pigmentation was observed and compared with that before use. The state of pigmentation was evaluated according to the criteria shown in Table 6, and the average value of 20 persons was calculated.

【表6】 [Table 6]

【0028】[0028]

【表2】 表2において、対照群では50週間のUVA照射によ
り、ほとんどのヘアレスマウスに深いしわの発生が認め
られている。本発明の実施例塗布群では、UVAによる
しわの発生に対して良好な防止効果が認められ、50週
照射後においても、微小なしわの発生が見られたのみで
あった。これに対し、比較例塗布群では、しわの発生の
進行は対照群に比べて遅いものの、その防止効果は実施
例塗布群よりも小さく、50週後には中程度のしわの発
生を認めたヘアレスマウスも見られた。
[Table 2] In Table 2, in the control group, generation of deep wrinkles was observed in almost all hairless mice by UVA irradiation for 50 weeks. In the group to which the examples of the present invention were applied, a good effect of preventing the generation of wrinkles due to UVA was recognized, and even after irradiation for 50 weeks, only the generation of minute wrinkles was observed. On the other hand, the wrinkle progression was slower in the control group than in the control group, but the preventive effect was smaller than in the control group, and the hairless group showed moderate wrinkle appearance after 50 weeks. Mice were also seen.

【0029】[0029]

【表3】 表3においても、対照群では1週間後に炎症の改善の認
められたヘアレスマウスはほとんどなく、わずかに1例
において若干の改善傾向を認めたのみであった。実施例
塗布群では、全例において改善傾向が認められ、実施例
1塗布群では3例、実施例3塗布群では4例のヘアレス
マウスにおいて改善を認めていた。これに対し、比較例
塗布群の改善は不十分で、改善の認められないものも比
較例1塗布群で1例、比較例2塗布群で3例見られた。
[Table 3] Also in Table 3, in the control group, almost no hairless mice showed improvement in inflammation after one week, and only one case showed a slight improvement tendency. In the group to which Example was applied, improvement was observed in all cases, and improvement was observed in 3 cases in the group to which Example 1 was applied and 4 cases in the group to which Example 3 was applied. On the other hand, the improvement of the group to which the comparative example was applied was insufficient and no improvement was observed.

【0030】[0030]

【表5】 表5より、本発明の実施例使用群では、良好な肌荒れ及
び色素沈着症状の改善が認められており、皮膚の状態は
ほぼ良好な状態まで回復し、色素沈着もわずかな程度に
まで改善されていることが示されている。一方、比較例
使用群では、肌荒れ及び色素沈着症状の改善傾向は認め
られるが、皮膚の状態は健康といえるところまで回復し
ておらず、軽度から中程度の色素沈着が相変わらず認め
られるなど、改善効果は不十分であった。
[Table 5] From Table 5, in the group using the examples of the present invention, favorable skin roughness and improvement of the pigmentation symptom were recognized, the skin condition was recovered to almost a good condition, and the pigmentation was also improved to a slight extent. Is shown. On the other hand, in the group using the comparative example, the tendency of improvement of the rough skin and the pigmentation symptom is observed, but the skin condition has not recovered to a point where it can be said to be healthy, and slight to moderate pigmentation is still observed. The effect was inadequate.

【0031】なお上記の使用試験において、本発明の実
施例1及び実施例3使用群では、皮膚刺激性及び皮膚感
作性を認めたパネラーは存在しなかった。また、本発明
の実施例1〜実施例7を25℃で3カ月間保存したとこ
ろ、状態の変化を認めたものはなかった。
In the above-mentioned use test, there was no paneler who recognized skin irritation and skin sensitization in the use groups of Examples 1 and 3 of the present invention. Further, when Examples 1 to 7 of the present invention were stored at 25 ° C. for 3 months, none of them showed any change in state.

【0032】[0032]

【発明の効果】以上詳述したように、本発明により老化
防止,抗炎症及び美白の各効果を合わせ持ち、且つ安定
性及び安全性に優れる皮膚外用剤を提供することができ
た。
As described in detail above, according to the present invention, it is possible to provide an external preparation for skin having both effects of anti-aging, anti-inflammatory and whitening, and excellent in stability and safety.

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】 ヤブコウジ科植物であるヤブコウジ(Ar
disia japonica Blume),シシアクチ(A. quinquegona
Blume),及びモクタチバナ(A. sieboldiMiq.)の抽
出物より選ばれる1種又は2種以上を含有することを特
徴とする皮膚外用剤。
1. An Aspergillus oryzae plant, Arbus japonica ( Ar
disia japonica Blume) and A. quinquegona
An external preparation for skin, characterized by containing one or more selected from extracts of Blume) and A. sieboldi Miq.
【請求項2】 ヤブコウジ科植物であるヤブコウジ(Ar
disia japonica Blume),シシアクチ(A. quinquegona
Blume),及びモクタチバナ(A. sieboldiMiq.)の抽
出物中に含まれる1,4-ベンゾキノン類より選ばれる、1
種又は2種以上を含有することを特徴とする、皮膚外用
剤。
2. An Aspergillus oryzae plant, Arbus japonica ( Ar
disia japonica Blume) and A. quinquegona
Blume) and 1,4-benzoquinones contained in the extract of A. sieboldi Miq.
An external preparation for skin, characterized by containing a seed or two or more kinds.
【請求項3】 皮膚外用剤が、皮膚用の化粧料であるこ
とを特徴とする、請求項1又は請求項2に記載の皮膚外
用剤。
3. The external preparation for skin according to claim 1, wherein the external preparation for skin is a cosmetic for skin.
JP8173082A 1996-06-11 1996-06-11 External preparation for skin Pending JPH101438A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP8173082A JPH101438A (en) 1996-06-11 1996-06-11 External preparation for skin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8173082A JPH101438A (en) 1996-06-11 1996-06-11 External preparation for skin

Publications (1)

Publication Number Publication Date
JPH101438A true JPH101438A (en) 1998-01-06

Family

ID=15953881

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8173082A Pending JPH101438A (en) 1996-06-11 1996-06-11 External preparation for skin

Country Status (1)

Country Link
JP (1) JPH101438A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11171784A (en) * 1997-12-09 1999-06-29 Noevir Co Ltd External preparation for skin
JP2002087973A (en) * 2000-09-08 2002-03-27 Kao Corp Cosmetics
JP2002145752A (en) * 2000-11-02 2002-05-22 Kose Corp Skin external preparation and skin external composition
KR100453217B1 (en) * 1998-05-15 2005-07-07 주식회사 엘지생활건강 Skin whitener

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11171784A (en) * 1997-12-09 1999-06-29 Noevir Co Ltd External preparation for skin
KR100453217B1 (en) * 1998-05-15 2005-07-07 주식회사 엘지생활건강 Skin whitener
JP2002087973A (en) * 2000-09-08 2002-03-27 Kao Corp Cosmetics
JP2002145752A (en) * 2000-11-02 2002-05-22 Kose Corp Skin external preparation and skin external composition

Similar Documents

Publication Publication Date Title
JP2003081749A (en) Skin care preparation
CN103494737B (en) Cosmetic preparation using ginger flower as anti-ageing and skin-protecting factor and preparation method of cosmetic preparation
KR20190023200A (en) Low irritating cosmetic composition for skin whitening
JP3667027B2 (en) Topical skin preparation
JPH08225428A (en) Cosmetics
JP2001122733A (en) Catalase production-promoting preparation and skin preparation for external use containing the same
JP2001114636A (en) Hyaluronic acid production and catalase production promoter, fibroblast activator, and skin external preparation
JPH101438A (en) External preparation for skin
JP3805022B2 (en) Topical skin preparation
JPH10194982A (en) Collagenase inhibitor and skin lotion for senescence prevention containing the same
JP5144362B2 (en) Topical skin preparation
JP2002370962A (en) Bleaching preparation and cosmetic for preventing and improving aging of skin
JPH10120546A (en) Skin whitening preparation for external use
JPH03200708A (en) Dermal external agent
JPH11171784A (en) External preparation for skin
JP3449967B2 (en) External preparation for skin
JPH01149706A (en) Skin-beautifying cosmetic
JPH01139517A (en) Cosmetic
JP2003095857A (en) Skin care preparation
JP2000143527A (en) Hyaluronic acid production promoter and skin preparation for external use containing the same
JP2007191452A (en) Estrogen-like active agent
JPH1149695A (en) Skin lotion for preventing aging
JP2004137166A (en) Skin care preparation for external use, cell activator and antioxidant
JP4011945B2 (en) Topical skin preparation
JP4473439B2 (en) Whitening agent

Legal Events

Date Code Title Description
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20060308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060313

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060512

RD05 Notification of revocation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7425

Effective date: 20060512

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20060601

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060703

A911 Transfer of reconsideration by examiner before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20060811

A912 Removal of reconsideration by examiner before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20070601